CEFTIN 125 MG / 5 ML
CEFUROXIME (CEFUROXIME AXETIL) : 125 MG / 5 ML · DIN 02212307 · SANDOZ CANADA INCORPORATED
Health Canada status: MARKETED
What is CEFTIN?
CEFTIN 125 MG / 5 ML contains CEFUROXIME (CEFUROXIME AXETIL) : 125 MG / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 02212307, held by SANDOZ CANADA INCORPORATED, supplied as GRANULES FOR SUSPENSION for ORAL administration. Health Canada currently lists it as marketed, status dated 28-Oct-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is CEFTIN called?
The same molecule, CEFUROXIME, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Zinnat | Latin | Australia, Morocco |
| Pharmacor Cefuroxime | Latin | Australia |
| Betaroxime | Latin | South Africa |
| CEROXIM | Latin | Morocco |
| Ceroxim Forte Suspension | Latin | South Africa |
| Ceroxim Suspension | Latin | South Africa |
| Furocsem | Latin | South Africa |
| Zinnat (UK) | Latin | Australia |
| Sandoz Cefuroxime | Latin | South Africa |
| ZINACEF | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02212307 |
|---|---|
| Brand name | CEFTIN |
| Generic / active ingredient | CEFUROXIME (CEFUROXIME AXETIL) : 125 MG / 5 ML |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 125 MG / 5 ML |
| Dosage form | GRANULES FOR SUSPENSION |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01DC02 CEFUROXIME |
| AHFS class | 08:12.06.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 28-Oct-2022 |
| Original market date | 1999-09-13 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02212307 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2212307 |
| Brand name | CEFTIN |
| Active ingredient / INN | CEFUROXIME (CEFUROXIME AXETIL) : 125 MG / 5 ML |
| ATC code | J01DC02 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01 |
| AHFS class | 08:12.06.08 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | SANDOZ CANADA INCORPORATED |
Which pack is which?
| Strength on the label | 125 MG / 5 ML |
|---|---|
| Dosage form | GRANULES FOR SUSPENSION |
| Route | ORAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
What can be used instead?
Other Canadian products sharing ATC code J01DC02 CEFUROXIME. 9 of 44 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-CEFUROXIME | 250 MG | TABLET | APOTEX INC | MARKETED | DIN 02244393 |
| APO-CEFUROXIME | 500 MG | TABLET | APOTEX INC | MARKETED | DIN 02244394 |
| AURO-CEFUROXIME | 250 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02344823 |
| AURO-CEFUROXIME | 500 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02344831 |
| CEFUROXIME FOR INJECTION, USP | 1.5 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02241639 |
| CEFUROXIME FOR INJECTION, USP | 750 MG | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02241638 |
| JAMP CEFUROXIME | 250 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02547198 |
| JAMP CEFUROXIME | 500 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02547201 |
| CEFTIN - PWR 250MG/SACHET | 250 MG | POWDER | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 02212293 |
| CEFTIN - TAB 250MG | 250 MG | TABLET | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 02212277 |
Who else supplies CEFUROXIME worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CEFUROXIME appears in 39 registered pack listings across 4 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does CEFUROXIME cost around the world?
CEFUROXIME is listed on 5 national price registers Nexara tracks, across 98 pack listings published on 5 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| South Africa | single exit price | 42 | 47 | 01 Sep 2026 |
| Greece | producer price (ex-factory) | 24 | 24 | 03 Sep 2026 |
| Morocco | PPV (public price) | 5 | 14 | 05 Sep 2026 |
| Australia | ex-manufacturer | 3 | 8 | 08 Sep 2026 |
| United Kingdom | hospital | 5 | 5 | 31 Aug 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.